c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

Abstract

Receptor tyrosine kinase (RTK) targeted agents such as trastuzumab, imatinib, bevacizumab, and gefitinib inhibitors have illustrated the utility of targeting this protein class for treatment of selected cancers. A unique member of the RTK family, c-Met, also represents an intriguing target for cancer therapy that is yet to be explored in a clinical setting… (More)

Topics

Cite this paper

@article{Christensen2005cMetAA, title={c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.}, author={James Christensen and Jon Burrows and Ravi Salgia}, journal={Cancer letters}, year={2005}, volume={225 1}, pages={1-26} }